ArticleEcoHealth2026
Diverse Reservoirs of Third-Generation Cephalosporin-Resistant Escherichia coli in Guatemala.
Article in EcoHealth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In Guatemala, there is a significant gap in our understanding of the prevalence of antibiotic resistance across different reservoirs likely to affect human exposures. We conducted a One Health study of produce, poultry, water, and humans within peri-urban and urban Guatemalan markets to characterize the prevalence of third-generation cephalosporin-resistant Escherichia coli (3GCR-EC). We screened a total of 132 samples for 3GCR-EC using selective media. Samples were collected across three markets in Guatemala and included produce (n = 32), public tap water (n = 30), commercial and non-commercial poultry (n = 40), and human fecal matter (n = 30). We measured phenotypic and genotypic resistance using culture-based methods and whole-genome sequencing. Among the 132 samples, 87.1% (n = 115) were positive for E. coli, and 67.4% (n = 43) were positive for 3GCR-EC. After removing duplicates, a total of 40 3GCR-EC isolates were sequenced from commercial chicken carcasses (n = 8), non-commercial chicken carcasses (n = 16), water (n = 4), and human feces (n = 12). Out of 11 unique extended-spectrum beta-lactamase genes, the most prevalent gene was bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.